H.C. Wainwright analyst Ed Arce raised the firm’s price target on Travere Therapeutics to $20 from $19 and keeps a Buy rating on the shares following the “strong quarter” for Filspari.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics, Inc. (TVTX) Q2 Earnings Cheat Sheet
- Travere Therapeutics to Report Second Quarter 2024 Financial Results
- Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)